Keymed Biosciences (HKSE:02162) Total Payout Ratio : -0.09 (As of Jun. 03, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Keymed Biosciences's current Total Payout Ratio is -0.09.

Keymed Biosciences Total Payout Ratio Historical Data

The historical data trend for Keymed Biosciences's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences Total Payout Ratio Chart

Keymed Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Payout Ratio

0.74

-0.17

-0.09

Keymed Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Payout Ratio	Get a 7-Day Free Trial				-	15.29	-0.04	0.60	-0.01

Competitive Comparison of Keymed Biosciences's Total Payout Ratio

For the Biotechnology subindustry, Keymed Biosciences's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keymed Biosciences's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's Total Payout Ratio falls into.

Keymed Biosciences Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Keymed Biosciences's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-35.986	+	0	+	0)	/	-389.591
	=	-0.09

Keymed Biosciences's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-4.536	+	0	+	0)	/	-442.251
	=	-0.01

Keymed Biosciences Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Keymed Biosciences (HKSE:02162) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

64Z:Germany

Address

No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219

Website

https://www.keymedbio.com

Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of innovative biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it operates in Hong Kong & Mainland China, out of which the majority is from Mainland China.

Executives

Chen Bo	2201 Interest of corporation controlled by you
Eagle Hero Management Limited	2101 Beneficial owner
Trident Trust Company (hk) Limited	2301 Trustee
Moonshot Holdings Limited	2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences (HKSE:02162) Headlines

No Headlines